MétaCan
Menu
Back to cohort
Record W4406698128 · doi:10.1093/ecco-jcc/jjae190.1303

P1129 Comparison of discontinuation/switching between adalimumab biosimilar and originator in Inflammatory Bowel Disease patients: Preliminary data from CAN-AIM

2025· article· en· W4406698128 on OpenAlexaffabout
Luck Lukusa, Marina Gabriela Birck, Cristiano Soares de Moura, Autumn Neville, Petros Zezos, Neeraj Narula, Laura E. Targownik, Christopher Ma, Eve Purdy, Waqqas Afif, Harminder Singh, B Oketola, Sasha Bernatsky

Bibliographic record

VenueJournal of Crohn s and Colitis · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsUniversity of ManitobaMcMaster UniversityThunder Bay Regional Health Sciences CentreMcGill UniversityUniversity of CalgaryNOSM UniversityMcGill University Health Centre
Fundersnot available
KeywordsMedicineBiosimilarAdalimumabInflammatory bowel diseaseDiscontinuationInfliximabInternal medicineDiseaseOncologyGastroenterology

Abstract

fetched live from OpenAlex

Abstract Background Biosimilar adalimumab (ADA-B) has been approved in Canada for inflammatory bowel disease (IBD) for over eight years, but real-world descriptions of therapy persistence (discontinuation/switching) comparing ADA-B to its bio-originator (ADA-O) are still scarce. We compared discontinuation of ADA-B and ADA-O in IBD. Methods CAN-AIM is a team funded to do high-priority research projects for Health Canada and other stakeholders. Canadian IBD Research Consortium members contributed to CAN-AIM’s prospective pan-Canadian clinical registry of biosimilar/bio-originator users. We enrolled adults with a clinical diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC), starting a bio-originator or corresponding biosimilar from Feb 2009 to Mar 2024. We assessed time to discontinuation through Kaplan-Meier curves with a log-rank test (right-censoring at loss to follow-up or end of study) and reasons for discontinuation. Using multivariable Cox regression, we assessed time to drug discontinuation, comparing ADA-B and ADA-O. Covariates included age, sex, underlying condition (CD/UC), disease duration, race and ethnicity, calendar year, smoking, education, disease activity (moderate or severe: Crohn’s Disease Activity Index ≥220, Harvey-Bradshaw Index ≥8 or Partial Mayo Score ≥5), obesity (body mass index >30), comorbidity, and prior use of other biologics, as well as previous/current corticosteroids and non-biologic immunosuppressants. Results We followed 103 IBD individuals for a median of 5.0 years (interquartile range of 3.6 to 9.2). IBD duration, age, race and ethnicity, and smoking were comparable among the two groups (Table 1). We censored four individuals who changed from ADA-O to ADA-B due to provincial drug insurance formulary requirements. There were 37 (35.9 %) other discontinuations, or 133.9 events per 1000 person-years. The main reasons for discontinuation were secondary loss of response (n=20, 54.1% of 37) and adverse events (n=7, 18.9%). Other reasons included insurance changes (n=2), patient choice (n=1), and unknown or missing reasons (n=7). Median time to discontinuation was 4.0 years (95% confidence interval [CI] 1.4-5.8) for ADA-O and 6.7 (95% CI 3.6-9.2) for ADA-B. Risk of discontinuation was lower in ADA-B versus ADA-O, with a wide CI (adjusted hazard ratio [aHR] 0.46, 95% CI 0.22–0.97 – Table 2). Older age, female sex, UC, higher education, more recent calendar year, and corticosteroids were significantly associated with discontinuation. Conclusion In this real-world IBD analysis, ADA-B was not associated with a greater risk of discontinuation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.030
Threshold uncertainty score0.439

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.318
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207